Editing Actithera

{{Company
|name=Actithera
|founded=~2024
|location=Norway & US
|category=Radiopharma / Radioligand Therapy
|funding=$75.5M Series A (Jul 2025)
}}

== What They Do ==
Radiopharmaceutical company developing radioligand therapies for cancer treatment. Radioligand therapy targets cancer cells with radioactive compounds, offering precision treatment with fewer side effects than traditional chemotherapy.<ref>pharmaphorum (Jul 2025): "New radiopharma Actithera emerges with $75.5m in financing"</ref>

== Revenue ==
'''Org nr:''' 935 938 341
'''Source:''' [https://www.proff.no/selskap/actithera-norway-as/oslo/forskning-og-utvikling/IFH8EN900FV proff.no]

* '''2024:''' N/A (no accounts filed)
* '''Employees:''' 1-4

Founded May 2025. Radiopharmaceutical company developing radioligand therapies for cancer. Norwegian subsidiary of Actithera Group AS. US operations. $75.5M Series A (Jul 2025).

== Funding ==
$75.5 million Series A (July 2025).<ref>ArcticStartup (Jul 10, 2025): "Norway & US-based Actithera raises $75.5M Series A to advance radioligand therapy pipeline"</ref>

Notably, Actithera secured this large Series A without a complete leadership team in place — defying typical VC expectations.<ref>BioXconomy (2025): "Defying Series A odds: How Actithera secured $75.5m without a leadership team"</ref> BioPharma Dive reported the company drew "new investors to radiopharma drug pitch."<ref>BioPharma Dive (2025): "Actithera draws new investors to radiopharma drug pitch"</ref>

European Biotechnology Magazine noted the deal reflects "huge momentum" in radiopharma funding globally.<ref>European Biotechnology Magazine (2025): "Actithera: Radiopharma Funding Gathers Huge Momentum"</ref>

== See Also ==
* [[Blood Tech]]
* [[Nordics]]
* [[Investors]]

<references />
[[Category:Company]]
[[Category:Norway]]